Acurx Pharmaceuticals Inc

ACXP

Company Profile

  • Business description

    Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.

  • Contact

    259 Liberty Avenue
    Staten IslandNY10305
    USA

    T: +1 917 533-1469

    https://www.acurxpharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    4

Stocks News & Analysis

stocks

ASX top pick remains cheap despite weaker consumer confidence

Consumer caution dents growth, shares look cheap.
stocks

Chart of the Week: Aussie dividend yields below 10-year average

Income opportunities remain beneath the surface.
stocks

Apple earnings: A smooth transition despite continued memory and supply headwinds

Shares fell as investors digested the latest earnings.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,205.20250.302.80%
CAC 408,205.3727.480.34%
DAX 4026,325.01112.66-0.43%
Dow JONES (US)51,825.221,530.90-2.87%
FTSE 10010,782.6646.55-0.43%
HKSE24,796.98877.483.67%
NASDAQ24,566.541,169.97-4.55%
Nikkei 22561,077.901,110.73-1.79%
NZX 50 Index14,090.97307.522.23%
S&P 5007,413.20275.42-3.58%
S&P/ASX 2009,065.10230.602.61%
SSE Composite Index3,689.913.740.10%

Market Movers